



December 18th, 2018
PeptiDream Inc.
<http://www.peptidream.com/>
(Ticker Code : 4587 TSE First Section)
Nihon Medi-Physics Co., Ltd.
<https://www.nmp.co.jp/>

PeptiDream & Nihon Medi-Physics Announce Strategic Alliance for the Discovery & Development of Peptide-based Theranostics

KANAGAWA, JAPAN and TOKYO, JAPAN – December 18th, 2018 – PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) and Tokyo-based Nihon Medi-Physics Co., Ltd. (“NMP”) announced today that they have entered into a multi-program strategic collaborative discovery and development agreement for the discovery and development of peptide-radioisotope (RI) conjugates for use as therapeutics and diagnostics.

PeptiDream has been using its proprietary Peptide Discovery Platform System (PDPS) technology for the identification of novel peptides for use as Peptide-Drug Conjugates (PDCs). NMP has been pursuing the fusion of therapeutics with diagnostics; “Theranostics”, and is a leader in the research, development, and manufacturing of radiopharmaceuticals. The two companies will work together across a variety of programs to conjugate PeptiDream’s constrained peptides with NMP’s radioisotopes to create a new exciting class of therapeutic and diagnostic products.

Under the terms of the deal, both companies will independently fund their efforts, and the development and commercialization rights will be shared between the companies under a cost-sharing structured arrangement. The companies will look to commercialize products in Japan & Asia, and potentially license out such products to the United States and Europe markets.

[Comment from Dr. Keiichi Masuya, Executive Vice President of PeptiDream Inc]

“We are extremely delighted to initiate this strategic alliance with NMP, a leader in the rapidly growing field of nuclear medicine, and a top manufacturer of radiopharmaceuticals and diagnostics. We believe that by combining our peptides with NMP’s radionucleotide labeling technology into peptide-RI conjugates, that we can develop a number of truly novel therapeutic and diagnostic products that would have a considerable impact on the treatment of patients worldwide.”

[Comment from Hisashi Shimoda, President of Nihon Medi-Physics Co., Ltd.]

“NMP aims to contribute to society by promoting the development of novel products and technologies, to address the unmet medical needs of the world. PeptiDream is the global leader in specialty peptides, with extensive experience and knowhow, and I am convinced that together we can achieve the realization of Theranostics, and bring a number of RI-conjugated peptide therapeutics and diagnostics to benefit patients worldwide.”

<About PeptiDream Inc.>

PeptiDream Inc. is a public (Tokyo Stock Exchange 1st Section 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide-based or small molecule-based therapeutics. PeptiDream aspires to be a world leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide. For further information, please visit www.peptidream.com

<About Nihon Medi-Physics Co., Ltd. (NMP)>

Nihon Medi-Physics is a Japanese leading company for radiopharmaceuticals who are dedicated in R&D and manufacturing of the radioactive medicine as well as to maintain its stable supply. The nuclear medicine scan using radiopharmaceuticals are considered useful for diagnosis of wide range of health problems such as stroke, dementia, heart disease, malignancy and so on. By capitalizing our technological capability and trust cultivated over the years through nuclear medicine diagnostic field in Japan, we aim the early realization of the innovative business beyond our existing business; “Realization of theranostics”, “Utilization of digital technology” and “Becoming the leading company of nuclear medicine in Asia”. We will continue to create corporate value and contribute to society. Please visit our website for more information. <https://www.nmp.co.jp>

Enquiries:

PeptiDream Inc.

Patrick C Reid +81-44-270-1270 (Kanagawa)

EMAIL: p-reid@peptidream.com

Nihon Medi-Physics Co., Ltd.

Soichi Nakamura +81-3-5634-7006 (Tokyo)

EMAIL: soichi_nakamura@nmp.co.jp